Technically Speakin...
Health Care: Drugs
Durect Corporation (DRRX: NASDAQ)
$0.82 -0.01 | -1.10%
06/04/12 - 09:38 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.83 |
| 52 Week High | 3.17 |
| 52 Week Low | 0.68 |
| Avg. Daily Vol. (Mil) | 0.36 |
| Beta (3 year) | 1.15 |
| Share Related Items | |
| Mkt Cap (Mil) | 72.65 |
| Shares Out (Mil) | 87.63 |
| Float (Mil) | 82.98 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.80 |
| Current Ratio | 5.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | 3.90 |
| Price/Sales | 1.10 |
| Price/Book | 2.02 |
| Price/Cash Flow | 3.70 |
| Per Share Data | |
| Earnings | 0.21 |
| Sales | 0.75 |
| Book Value | 0.41 |
| Cash Flow | 0.22 |
| Business Summary | |
|---|---|
| Durect Corporation is a pharmaceutical company which is developing therapies based on its proprietary drug formulations and delivery platform technologies. | |
| General Information | |
| 2 Results Way
Cupertino, CA 95014 |
|
| www.durect.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 106 | |
| CEO: James E. Brown,D.V.M. | |
| Short Interest | |
| Current Month (Mil) | 3.49 |
| Previous Month (Mil) | 3.17 |
| Short Interest Ratio (Days) | 14.80 |
| Management Effectiveness | |
| Return on Equity | 51.20 |
| Return on Assets | 42.20 |
| Return on Investments | 51.20 |
| Profitability | |
| Gross Margin | 94.40 |
| EBIT Margin | 28.00 |
| Profit Margin | 27.90 |
Portfolios with DRRX
- Portfolio NameUser Type
- ProRobert Bruce
- Userdonellisor
- UserTrading
- Userbaustin002 Portfolio 1
- UserBarron's Research Reports 1...
- Userhititbig
- Userbv2
- UserFBSPANKEY Portfolio 1
- Usersandw1ch Portfolio 1
- Usermiguele4 Portfolio 1
Latest DRRX Headlines from TheStreet
- Business Highlights 06.24.11 | 06:06 pm
- Durect Stock Gaps Down On Today's Open (DRRX) 06.24.11 | 09:06 am
- Pfizer, Pain Therapeutics Drug Rejected by FDA 06.24.11 | 08:06 am
- 10 Stocks to Watch: Alcoa, BP 04.12.11 | 06:04 am
- Biotech Calendar: 2011 FDA Drug Approvals 02.22.11 | 07:02 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences 09.07.10 | 06:09 pm
- DURECT Corporation Q1 2010 Earnings Call Transcript 05.11.10 | 01:05 am
- Durect Says Pain Patch Met Goals In Clinical Study 03.16.09 | 02:03 pm
- Thursday's Winners & Losers: Durect 05.08.08 | 04:05 pm
- Health Winners & Losers: Barr 05.08.08 | 04:05 pm
Press Releases for DRRX
- DURECT Receives Back U.S. And Canadian Product Rights To POSIDUR⢠- PR Newswire 03.29.12 | 04:03 pm
- DURECT Corporation Invites You To Join Its Fourth Quarter 2011 Earnings Conference Call - PR Newswire 02.24.12 | 09:02 am
- DURECT To Participate In Upcoming Healthcare Conferences - PR Newswire 02.23.12 | 11:02 am
- DURECT To Present At The BIO CEO & Investor Conference - PR Newswire 02.07.12 | 12:02 pm
- DURECT Receives Back European Product Rights To POSIDUR⢠- PR Newswire 01.30.12 | 04:01 pm
- DURECT Announces Top-line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial) - PR Newswire 01.05.12 | 04:01 pm
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 11.07.11 | 08:11 am
- DURECT Corporation Invites You To Join Its Third Quarter 2011 Earnings Conference Call - PR Newswire 10.26.11 | 05:10 pm
- DURECT Completes Enrollment In Pivotal U.S. Phase III Trial For POSIDUR® (BESST) - PR Newswire 09.06.11 | 07:09 am
- DURECT Corporation To Participate In Upcoming Healthcare Conferences - PR Newswire 08.31.11 | 04:08 pm
Partner Headlines for DRRX
- Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT - Benzinga 03.01.12 | 04:03 pm
- DURECT Announces Top-line Data from BESST; Did Not Reach Statistical Significance - Benzinga 01.05.12 | 04:01 pm
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
- Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX) - Benzinga 08.05.10 | 09:08 am
- FDA Clears Hospira's Generic Drug - Analyst Blog - Zacks 06.25.10 | 01:06 pm
- UPDATE 1-Durect's pain drug shows mixed results in EU trial - Reuters 06.16.10 | 05:06 pm
- King Advances Pain Candidate - Analyst Blog - Zacks 04.08.10 | 06:04 pm
